Chronic Stress Lets Gut Bacteria Hijack Tumors and Shut Down Immune Defenses
A newly discovered phage-fibroblast-B cell circuit explains how chronic stress drives tumor growth by suppressing anti-tumor immunity.
Summary
Scientists have uncovered a surprising chain of events linking chronic stress to faster tumor growth. Under prolonged stress, gut bacteria — specifically a pathobiont called Enterococcus gallinarum — migrate into tumors. Once inside, viral DNA from these bacteria (phage DNA) triggers tumor-associated fibroblasts to produce glucocorticoids, the same stress hormones that suppress immune function. These locally produced glucocorticoids then shut down B cell responses that would normally help fight the cancer. Blocking this pathway — either by targeting a key immune receptor (TLR9) or by eliminating the bacteria — reversed the tumor-promoting effects of stress in mouse models of colorectal cancer and melanoma. Similar phage DNA was found in human colorectal and brain tumors, suggesting this mechanism may be clinically relevant.
Detailed Summary
Chronic psychological stress has long been associated with worse cancer outcomes, but the biological mechanisms connecting stress to tumor progression have remained poorly understood. This landmark study from Weill Cornell Medicine and collaborating institutions reveals a previously unknown circuit — involving gut bacteria, intratumoral fibroblasts, and B cells — that explains how stress accelerates cancer growth.
The researchers found that chronic stress disrupts the gut microbiome in cancer patients and that gut bacteria are actually required for stress-induced glucocorticoid (stress hormone) production. Using mouse models of colorectal cancer and melanoma, the team demonstrated that chronic stress causes a gut pathobiont, Enterococcus gallinarum, to translocate from the gut into tumors. This bacterial migration is not benign: inside tumors, phage DNA from these bacteria activates TLR9 receptors on cancer-associated fibroblasts (CAFs), which then produce glucocorticoids locally within the tumor microenvironment.
These intratumoral glucocorticoids suppress germinal center B cell responses — a critical arm of adaptive anti-tumor immunity — via the glucocorticoid receptor. The net effect is a weakened immune attack on the tumor, giving cancer cells room to proliferate. Crucially, targeting intratumoral TLR9 signaling or eliminating Enterococcus gallinarum significantly reduced intratumor glucocorticoid levels and reversed the tumor-promoting effects of chronic stress.
Extending to human cancer, the team identified lytic phages in a Klebsiella pneumoniae isolate from human colorectal tumors and detected phage DNA in human brain tumors, suggesting this stress-microbiome-immunity axis operates in people as well.
Caveats include that full mechanistic details are available only from the abstract, mouse models may not fully replicate human tumor biology, and the clinical translatability of TLR9 or bacterial targeting strategies requires further investigation.
Key Findings
- Chronic stress causes gut bacteria (Enterococcus gallinarum) to migrate into tumors, suppressing anti-tumor immunity.
- Phage DNA from intratumoral bacteria triggers fibroblasts to produce glucocorticoids via TLR9, shutting down B cell responses.
- Blocking TLR9 or eliminating the pathobiont reversed stress-driven tumor growth in mouse models.
- Phage DNA was detected in human colorectal and brain tumors, suggesting clinical relevance.
- Gut microbiota are required for stress-induced glucocorticoid production, linking stress, microbiome, and immune suppression.
Methodology
The study used mouse models of colorectal cancer and melanoma to dissect the chronic stress-tumor growth axis, combining microbiome manipulation, genetic tools targeting TLR9 and glucocorticoid receptors, and B cell response assays. Human colorectal tumor isolates and brain tumor samples were analyzed for phage DNA to validate translational relevance. Full methodology details are limited as only the abstract was available.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, so mechanistic and statistical details cannot be fully evaluated. Mouse models of colorectal cancer and melanoma may not perfectly replicate the complexity of human tumor microenvironments. The clinical translation of TLR9 targeting or microbiome interventions in human cancer patients requires prospective validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: